Livzon Pharmaceutical Group Inc.
000513
株式のランク
#4689
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
株価
$3.90
時価総額
$3.17B
変化（1日）
-3.49%
変化（1年）
-25.88%
国
CN
取引 Livzon Pharmaceutical Group Inc. (000513)
カテゴリー
Healthcare
Livzon Pharmaceutical Group Inc.（000513）のP/E比率
October 2026 時点のP/E比率 TTM 13.77
Livzon Pharmaceutical Group Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は 13.77 です。2024 年末時点での P/E は 16.96 でした。
Livzon Pharmaceutical Group Inc. の P/E 比率の履歴（2001 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 13.77 | -9.31% |
| 2025 | 15.18 | -10.51% |
| 2024 | 16.96 | 1.26% |
| 2023 | 16.75 | 5.33% |
| 2022 | 15.90 | -24.84% |
| 2021 | 21.16 | -4.29% |
| 2020 | 22.11 | -8.56% |
| 2019 | 24.18 | 53.26% |
| 2018 | 15.78 | 89.27% |
| 2017 | 8.34 | -72.32% |
| 2016 | 30.11 | -15.07% |
| 2015 | 35.45 | 24.91% |
| 2014 | 28.38 | 21.00% |
| 2013 | 23.45 | 0.46% |
| 2012 | 23.35 | 39.28% |
| 2011 | 16.76 | -46.06% |
| 2010 | 31.07 | 26.38% |
| 2009 | 24.59 | -75.97% |
| 2008 | 102.32 | 294.87% |
| 2007 | 25.91 | 94.93% |
| 2006 | 13.29 | 12.29% |
| 2005 | 11.84 | -26.37% |
| 2004 | 16.08 | -20.45% |
| 2003 | 20.21 | -49.08% |
| 2002 | 39.69 | -23.54% |
| 2001 | 51.91 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 23.30 | 69.23% |
DE
|
|
| 26.92 | 95.52% |
DE
|
|
| 55.58 | 303.69% |
JP
|
|
| 61.13 | 344.05% |
CH
|
|
| 34.87 | 153.31% |
IN
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。